Hubei Biocause Pharmaceutical Co., Ltd. (SHE: 000627)

Market Cap	13.04B
Revenue (ttm)	43.92B
Net Income (ttm)	-829.39M
Shares Out	4.94B
EPS (ttm)	-0.17
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	151,407,884
Open	2.640
Previous Close	2.640
Day's Range	2.640 - 2.900
52-Week Range	1.610 - 3.430
Beta	0.37
Analysts	n/a
Price Target	n/a
Earnings Date	Oct 30, 2024

About Hubei Biocause Pharmaceutical

Hubei Biocause Pharmaceutical Co., Ltd. primarily provides life and motor insurance products in China. It also engages in the pharmaceutical, chemical, and new energy fuel businesses. In addition, the company is involved in the contract research and production of APIs, intermediates, and formulations, including tablets, granules, capsules, etc.; and provision of chemicals comprising dimethyl ether gas and a-chloropropionyl chloride. It exports its products to approximately 85 countries, including the United States, the European Union, and inter...

• Industry: Insurance - Life
• Sector: Financials
• CEO: Wenxia Zhou
• Employees: 1,765
• Stock Exchange: Shenzhen Stock Exchange
• Ticker Symbol: 000627